Ratings BRAIN Biotech AG

Equities

BNN

DE0005203947

Market Closed - Xetra Other stock markets 11:36:01 2024-04-26 am EDT			5-day change	1st Jan Change
2.88 ^EUR	+4.73%		+0.70%	-21.31%

Apr. 16	Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery	MT
Mar. 05	BRAIN Biotech AG and AMSilk GmbH Announce the Successful Completion of the First Phase of A Development Collaboration	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Sales forecast by analysts have been recently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The group shows a rather high level of debt in proportion to its EBITDA.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Environmental Services & Equipment

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BRAIN BIOTECH AG	-21.31%	67.17M		-
AVANTIUM N.V.	-29.08%	213M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes